Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)

Aman U. Buzdar; George R. Blumenschein; Terry L. Smith; Charles K. Tashima; Gabriel N. Hortobagyi; H. Yong Yap; Jordan U. Gutterman; Evan M. Hersh; Edmund A. Gehan

doi:10.1002/jso.2930120105

Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)

Aman U. Buzdar, George R. Blumenschein, Terry L. Smith, Charles K. Tashima, Gabriel N. Hortobagyi, H. Yong Yap, Jordan U. Gutterman, Evan M. Hersh, Edmund A. Gehan

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

A combination of 5‐fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC‐BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P < 0.01). Estimated 2‐year survival rate from first recurrence was 85% for the FAC‐BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease‐free interval from the first recurrence, but additional follow‐up is needed to determine its effect on long‐term survival.

Original language	English (US)
Pages (from-to)	27-40
Number of pages	14
Journal	Journal of surgical oncology
Volume	12
Issue number	1
DOIs	https://doi.org/10.1002/jso.2930120105
State	Published - 1979

Keywords

adjuvant chemotherapy
isolated recurrence of breast cancer

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.2930120105

Cite this

@article{0daa8982aa224fb09d5364e52985fa8f,

title = "Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)",

abstract = "A combination of 5‐fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC‐BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P < 0.01). Estimated 2‐year survival rate from first recurrence was 85% for the FAC‐BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease‐free interval from the first recurrence, but additional follow‐up is needed to determine its effect on long‐term survival.",

keywords = "adjuvant chemotherapy, isolated recurrence of breast cancer",

author = "Buzdar, {Aman U.} and Blumenschein, {George R.} and Smith, {Terry L.} and Tashima, {Charles K.} and Hortobagyi, {Gabriel N.} and Yap, {H. Yong} and Gutterman, {Jordan U.} and Hersh, {Evan M.} and Gehan, {Edmund A.}",

year = "1979",

doi = "10.1002/jso.2930120105",

language = "English (US)",

volume = "12",

pages = "27--40",

journal = "Journal of surgical oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)

AU - Buzdar, Aman U.

AU - Blumenschein, George R.

AU - Smith, Terry L.

AU - Tashima, Charles K.

AU - Hortobagyi, Gabriel N.

AU - Yap, H. Yong

AU - Gutterman, Jordan U.

AU - Hersh, Evan M.

AU - Gehan, Edmund A.

PY - 1979

Y1 - 1979

N2 - A combination of 5‐fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC‐BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P < 0.01). Estimated 2‐year survival rate from first recurrence was 85% for the FAC‐BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease‐free interval from the first recurrence, but additional follow‐up is needed to determine its effect on long‐term survival.

AB - A combination of 5‐fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC‐BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P < 0.01). Estimated 2‐year survival rate from first recurrence was 85% for the FAC‐BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease‐free interval from the first recurrence, but additional follow‐up is needed to determine its effect on long‐term survival.

KW - adjuvant chemotherapy

KW - isolated recurrence of breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0018370222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018370222&partnerID=8YFLogxK

U2 - 10.1002/jso.2930120105

DO - 10.1002/jso.2930120105

M3 - Article

C2 - 480951

AN - SCOPUS:0018370222

SN - 0022-4790

VL - 12

SP - 27

EP - 40

JO - Journal of surgical oncology

JF - Journal of surgical oncology

IS - 1

ER -

Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this